VASO Vaso Corporation (QX)

Vasomedical, Inc. ("Vasomedical") (OTCBB:VASO), a world leader in the noninvasive treatment of cardiovascular diseases, today announced the release of the iPhone for EECP® Therapy application (http://www.vasomedical.com/eecptherapyapp.html), which provides current and potential patients, physicians, therapists and other interested parties a mobile source of information and support materials for EECP® therapy, the company's proprietary Enhanced External Counterpulsation technology cleared by the US FDA for noninvasive treatment of certain cardiovascular diseases.

Available for free at the iPhone App Store, the Vasomedical EECP® Therapy iPhone App allows patients, physicians and therapists to easily obtain information on patient selection, clinical guidelines for treatment and user tools to optimize treatment. Current and potential patients can access information to learn about EECP® therapy and its benefits as well as to identify symptoms that they can discuss with their physicians to see if EECP® therapy could eliminate or reduce their symptoms and improve their quality of life. In addition, the iPhone application includes a Treatment Locator which, based on the iPhone user's current location or an inputted ZIP code, pinpoints on the map the locations of the closest EECP® treatment centers throughout the United States. The app is available for download in the App Store on the iPhone or in iTunes and can be found by searching "EECP" or "Vasomedical."

"The new iPhone App is another example of Vasomedical's use of innovation and cutting edge technology to provide information to both the public and clinical professional about EECP® therapy in our ongoing mission to create greater awareness for the therapy," stated Larry Liebman, Vice President of Sales and Marketing for Vasomedical. "The iPhone App, the Vasomedical web sites (www.Vasomedical.com and www.EECP.com) and the EECP Forum (www.EECPForum.com) are all designed to increase awareness and patient access to the highly successful and reimbursed noninvasive treatment, EECP® therapy, which has scientifically demonstrated its ability to improve patient outcomes and reduce healthcare costs."

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system. Through its sales representative agreement with GE Healthcare, the Company is also engaged as an exclusive sales representative for certain GE Healthcare products. Additional information is available on the Company's website at www.vasomedical.com.

VasoHealthcare™, a wholly owned subsidiary of Vasomedical Inc. is a professional sales representation company offering vendors an alternative third party sales channel. Additional information is available at www.vasohealthcare.com.

The Vasomedical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7756

CONTACT:  Vasomedical, Inc.
          Dr. Jun Ma, President and CEO
            516-997- 4600
          David Singh, CFO
            516-997- 4600
          Investor Relations:
            customerservice@vasomedical.com